NCT04370483 2026-01-05
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
11 trialsNCT04508790 2025-08-07
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
Phase 2 Recruiting
NCT03709446 2025-07-08
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT05443425 2025-07-04
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
City of Hope Medical Center
Phase 1 Recruiting
NCT04997993 2025-06-25
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Recruiting
NCT06454383 2025-04-10
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06540937 2024-08-07
Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06229340 2024-01-29
NТО-RAS
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Recruiting
NCT01727193 2022-04-14
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Completed
NCT03952832 2019-11-14
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
Phase 2 Withdrawn
NCT01611675 2017-04-06
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Massachusetts General Hospital
Phase 1 Terminated